Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond

伊库利珠单抗 补体系统 阵发性夜间血红蛋白尿 免疫学 非典型溶血尿毒综合征 医学 补体成分5 凝集素途径 补语(音乐) 替代补体途径 免疫系统 生物 遗传学 基因 表型 互补
作者
Eleni Gavriilaki,Régis Peffault de Latour,Antonio M. Risitano
出处
期刊:Blood [Elsevier BV]
卷期号:139 (25): 3571-3582 被引量:26
标识
DOI:10.1182/blood.2021012860
摘要

Complement is an elaborate system of innate immunity. Genetic variants and autoantibodies leading to excessive complement activation are implicated in a variety of human diseases. Among them, the hematologic disease paroxysmal nocturnal hemoglobinuria (PNH) remains the prototypic model of complement activation and inhibition. Eculizumab, the first-in-class complement inhibitor, was approved for PNH in 2007. Addressing some of the unmet needs, a long-acting C5 inhibitor, ravulizumab, and a C3 inhibitor, pegcetacoplan, have also now been approved for PNH. Novel agents, such as factor B and factor D inhibitors, are under study, with very promising results. In this era of several approved targeted complement therapeutics, selection of the proper drug must be based on a personalized approach. Beyond PNH, complement inhibition has also shown efficacy and safety in cold agglutinin disease, primarily with the C1s inhibitor of the classical complement pathway sutimlimab, as well as with pegcetacoplan. Furthermore, C5 inhibition with eculizumab and ravulizumab, as well as inhibition of the lectin pathway with narsoplimab, is being investigated in transplantation-associated thrombotic microangiopathy. With this revolution of next-generation complement therapeutics, additional hematologic entities, such as delayed hemolytic transfusion reaction or immune thrombocytopenia, might also benefit from complement inhibitors. Therefore, this review aims to describe state-of-the-art knowledge of targeting complement in hematologic diseases, focusing on (1) complement biology for the clinician, (2) complement activation and therapeutic inhibition in prototypic complement-mediated hematologic diseases, (3) hematologic entities under investigation for complement inhibition, and (4) other complement-related disorders of potential interest to hematologists.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
2秒前
大老黑完成签到,获得积分10
2秒前
2秒前
health__up完成签到,获得积分10
2秒前
bkagyin应助江子采纳,获得10
2秒前
leez完成签到,获得积分10
4秒前
诸道罡完成签到,获得积分10
5秒前
5秒前
洋洋发布了新的文献求助10
5秒前
超帅凡阳发布了新的文献求助10
6秒前
FIN应助麦田守望者采纳,获得30
7秒前
明天见发布了新的文献求助10
8秒前
口腔小废物完成签到 ,获得积分10
8秒前
ohh完成签到,获得积分10
10秒前
10秒前
英俊的铭应助快乐源泉采纳,获得10
11秒前
羊羊羊完成签到,获得积分10
11秒前
嘒彼小星完成签到 ,获得积分10
12秒前
小洪俊熙完成签到,获得积分10
13秒前
Hello应助stronger采纳,获得10
13秒前
13秒前
Ellie完成签到 ,获得积分10
14秒前
15秒前
15秒前
田様应助郭小宝采纳,获得10
15秒前
16秒前
所所应助aka鱼鱼鱼采纳,获得10
16秒前
18秒前
18秒前
xiaohu6311发布了新的文献求助10
19秒前
Jasper应助古夕采纳,获得10
19秒前
xiaowang发布了新的文献求助10
19秒前
张二狗发布了新的文献求助30
19秒前
瑶啊瑶完成签到,获得积分10
20秒前
daimin发布了新的文献求助10
21秒前
21秒前
sundial发布了新的文献求助10
21秒前
zzh完成签到 ,获得积分10
21秒前
成就的翠琴完成签到,获得积分10
22秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Economic Geography and Public Policy 900
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988786
求助须知:如何正确求助?哪些是违规求助? 3531116
关于积分的说明 11252493
捐赠科研通 3269766
什么是DOI,文献DOI怎么找? 1804771
邀请新用户注册赠送积分活动 881870
科研通“疑难数据库(出版商)”最低求助积分说明 809021